BioCentury
ARTICLE | Company News

Moderna announces pipeline updates in first financial results

March 7, 2019 11:21 PM UTC

In its first quarterly financial results as a public company, Moderna announced its first rare disease mRNA program is heading to the clinic.

Moderna Inc. (NASDAQ:MRNA) said Wednesday that it has submitted an IND for mRNA-3704 to treat methylmalonic acidemia, and the company is preparing to begin a Phase I/II trial. It did not disclose a timeline. It said FDA granted Fast Track designation to the therapy, a liver-specific mRNA targeting the methylmalonyl CoA mutase (MUT) gene...

BCIQ Company Profiles

Moderna Inc.

BCIQ Target Profiles

Methylmalonyl CoA mutase (MUT)